Post Wed Mar 30, 2016 11:00 pm

2015-Das et al-J Immunol.

"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo"
Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.
J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.

http://dx.doi.org/10.4049/jimmunol.1401686

This publication takes a broad exploratory approach to investigating the immune response to the checkpoint inhibitors anti-PD-1 and CTLA-4. The authors compare immune cells from patients undergoing monotherapy, combination therapy and sequential therapy. CyTOF is used to take a deeper dive into an immune subset of interest (CD3+CD4+ Ki67+ and CD3+CD8+ Ki67+ cells, figure 2C).

Immuno-oncology is the hottest field in cancer therapy these days. With this approach immune cells are the potentiators of the anti-cancer response. For an immunology buff like me these are very exciting times :ugeek: